Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update

Melanoma and Skin Cancer

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

J Clin Oncol

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D

doi: 10.1200/JCO.24.01125

Melanoma and Skin Cancer

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

Melanoma Res

González-Barrallo I, Castellón Rubio VE, Medina J, España Fernández S, Mujika K, Majem M, Aguado C, Cabrera Suárez MÁ, Palacio I, Osterloh L, Martínez-Fernández A, García-Castaño A

doi: 10.1097/CMR.0000000000001020

Melanoma and Skin Cancer

Melanoma: Assessment and Management summary of 2022 update of the NICE guidelines

Br J Dermatol

Smith MJ, Peach H, Keohane S, Lear J, Jamieson LA, Mohamed HS, NICE Melanoma Assessment and Management guideline committee

doi: 10.1093/bjd/ljaf016

ImmunotherapyFurther Publications Dermatology

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Lancet

Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Peña AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M, CheckMate 9DW investigators

doi: 10.1016/S0140-6736(25)00403-9

Melanoma and Skin Cancer

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Melanoma Res

Macaire C, Lefevre W, Dalac S, Montaudié H, Legoupil D, Dereure O, Dutriaux C, Leccia MT, Aubin F, Grob JJ, Saiag P, De Quatrebarbes J, Maubec E, Lesimple T, Granel-Brocard F, Mortier L, Dalle S, Lebbé C, Prod'homme C

doi: 10.1097/CMR.0000000000000973

Melanoma and Skin Cancer

Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma

Melanoma Res

Paolino G, Podo Brunetti A, De Rosa C, Cantisani C, Rongioletti F, Carugno A, Zerbinati N, Valenti M, Mascagni D, Tosti G, Mercuri SR, Pampena R

doi: 10.1097/CMR.0000000000001003

Melanoma and Skin Cancer

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma

Br J Dermatol

McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, Hwang AS, Zhang K, Barros M, Yeh J, Okazaki I, Crocker AB, Maeda T, Park SJ, Choi J, Andreoli M, Darwish T, Savage DJ, Kim KB, Gupta J, Shen J, Shirai K, Choi A, Pai L, de Lima Vazquez V, Moser J, Amaral T, Hernandez Aya LF, Lutzky J, Najjar YG, Costello CM, Mangold AR, Bhatia S, Gibney GT, Farma JM, Daniels GA, Sosman J, Chandra S, Mangla A, Bollin K, Abrão Possik P, Robles Espinoza CD, Ito F, In GK

doi: 10.1093/bjd/ljae401

Melanoma and Skin Cancer

The risk of ultraviolet exposure for melanoma in Fitzpatrick skin types I-IV: A 20-year systematic review with meta-analysis for sunburns

J Eur Acad Dermatol Venereol

Kwa M, Ravi M, Elhage K, Schultz L, Lim HW

doi: 10.1111/jdv.20316

Melanoma and Skin Cancer

The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study

Ann Dermatol Venereol

Amici M, Neveu E, Poizeau F, Edeline J, Lesimple T, Oger E, Danton G, Dupuy A, Fouchard M

doi: 10.1016/j.annder.2025.103371

Related content

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

Melanoma: Assessment and Management summary of 2022 update of the NICE guidelines

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort

Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma

Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma

The risk of ultraviolet exposure for melanoma in Fitzpatrick skin types I-IV: A 20-year systematic review with meta-analysis for sunburns

The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study